Pier Capital, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Pier Capital, LLC

$670 Million
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$83.14 - $145.99 $3.03 Million - $5.33 Million	-36,491 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$110.08 - $142.92 $5.44 Million - $7.06 Million	-49,411 Reduced 57.52%	36,491 $4.33 Million
Q4 2021 Feb 10, 2022	SELL	$99.73 - $148.48 $130,746 - $194,657	-1,311 Reduced 1.5%	85,902 $11.8 Million
Q3 2021 Nov 10, 2021	SELL	$98.85 - $138.91 $2.64 Million - $3.71 Million	-26,705 Reduced 23.44%	87,213 $12.1 Million
Q2 2021 Aug 12, 2021	SELL	$65.78 - $105.02 $3.22 Million - $5.15 Million	-49,016 Reduced 30.08%	113,918 $11.1 Million
Q1 2021 May 13, 2021	BUY	$64.07 - $91.75 $6.17 Million - $8.84 Million	96,322 Added 144.6%	162,934 $11.1 Million
Q4 2020 Feb 16, 2021	BUY	$65.07 - $98.24 $137,753 - $207,974	2,117 Added 3.28%	66,612 $5.71 Million
Q3 2020 Nov 13, 2020	SELL	$59.04 - $77.95 $47,999 - $63,373	-813 Reduced 1.24%	64,495 $4.19 Million
Q2 2020 Aug 13, 2020	SELL	$29.01 - $74.23 $1.07 Million - $2.73 Million	-36,726 Reduced 35.99%	65,308 $4.78 Million
Q1 2020 May 15, 2020	BUY	$27.51 - $57.29 $966,563 - $2.01 Million	35,135 Added 52.52%	102,034 $3.47 Million
Q4 2019 Feb 14, 2020	SELL	$40.86 - $57.65 $1.72 Million - $2.42 Million	-42,026 Reduced 38.58%	66,899 $3.64 Million
Q3 2019 Nov 13, 2019	SELL	$37.38 - $49.47 $173,817 - $230,035	-4,650 Reduced 4.09%	108,925 $4.54 Million
Q2 2019 Aug 14, 2019	BUY	$39.79 - $67.01 $1.78 Million - $3 Million	44,786 Added 65.11%	113,575 $4.97 Million
Q1 2019 Apr 24, 2019	BUY	$34.52 - $53.29 $2.37 Million - $3.67 Million	68,789 New	68,789 $3.54 Million

Others Institutions Holding BHVN

# of Institutions

Shares Held

792K

Call Options Held

Put Options Held

View Full List

About Biohaven Pharmaceutical Holding Co Ltd.

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

More about BHVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pier Capital, LLC with notifications on news.

Account